Pharmacology and Pharmaceutical Sciences articles for Spain

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 65

Article ‘Count’ for Pharmacology and Pharmaceutical Sciences.

Journal Count Share
1 0.08
Ce6-DNAzyme-Loaded Metal–Organic Framework Theranostic Agents for Boosting miRNA Imaging-Guided Photodynamic Therapy in Breast Cancer 0.08
3 2.66
Intrinsic Photoactive Star ZnPc–Poly(glutamate) Nanoplatforms for Multimodal Glioblastoma Therapy and Brain-Targeted Delivery 0.93
4D-Printable Poly(Thio)urethane Photoresins With Reactive Oxygen Species Responsiveness and Anti-Inflammatory Functionality 0.73
Evolving Platinum-Copper Nanostructures for Enhanced Photothermal Therapy and Controlled Copper Release in Cancer Therapy 1.00
4 3.18
iDeepLC: Chemical Structure Information Yields Improved Retention Time Prediction of Peptides with Unseen Modifications 0.18
3D Glioblastoma Molecular Responses to Carbon Dot–Delivered Riluzole Probed by Synchrotron FTIR 1.00
Toward AI-Assisted Greener Chiral HPLC: Predicting Efficient Enantioseparation–Mobile Phase (EES–MP) Profiles for MP Selection─A Lux Cellulose-1 Case Study 1.00
Serum-Based Detection of Pancreatic and Ovarian Cancer via a Nanoparticle-Enhanced Fluorescence Array and Machine Learning 1.00
3 0.93
Fluorinative Rearrangement of Vinyl Diazo Compounds Enabled by a New Reactivity Mode of Cyclopropanediazonium Ions 0.13
Design, Synthesis, and Structural Evolution of Pseudo‐Natural Product IDO1 Inhibitors and Degraders 0.05
Tailored Core‐Shell Nanocarrier for Therapeutic Drug Delivery via Visible Light Activation 0.75
1 0.06
Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study 0.06
1 0.02
Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step toward Precision Drug Monitoring 0.02
1 0.20
The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors 0.20
1 1.00
B–N axis as a facilitating agent for the synthesis of 3D structures: the paradigmatic case of BN-[4.4.4]propellane 1.00
3 0.84
Safety of short-course weekly rifapentine and isoniazid (3HP) for TB preventive treatment at conception and during first trimester in women living with HIV: a secondary analysis of WHIP3TB trial 0.04
Targeted Peri-operative Prophylaxis in Patients Colonized With Carbapenem Resistant Enterobacterales Undergoing Liver Transplantation: A Multinational Cohort Study 0.07
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials 0.73
2 0.14
The Association of Blood Lead with Cardiovascular Disease Incidence and Mortality: Findings from the Strong Heart Study Cohort 0.04
Time-Varying Exposure to Element Mixtures and Children’s Cognition at 5 Years of Age: Findings from the New Hampshire Birth Cohort Study 0.10
3 2.03
Biomonitoring of DAPs levels in urine and amniotic fluid of pregnant women in Seville (Spain): evaluation of prenatal exposure 1.00
Exposure to mixed metals/metalloids in early childhood: a cross-sectional cohort study in children from Sevilla, Southern Spain 1.00
Per- and polyfluoroalkyl substances exposure in hexavalent chromium exposed workers and the effects of exposure mixtures on oxidative stress and genomic instability 0.03
5 3.92
Prenatal cadmium exposure and behavioural and emotional problems across childhood: findings from the INMA birth cohort 0.88
Human biomonitoring of plasma trace elements in Brazilian adults: distribution patterns and sociodemographic determinants in the ELSA-Brasil cohort 0.11
Age at menarche and exposure to non-persistent pesticides in Spanish girls from the INMA (Environment and Childhood) Project 0.98
Association between Arsenic Levels in Toenails and Urine and Prostate Cancer Risk: Findings from the MCC-Spain study 1.00
Mixtures of chemicals in pregnancy and their effects on cognitive and fine motor abilities in childhood 0.95
2 0.66
Evaluating the Incorporation of Picolinamide Pendants into the Macropa Scaffold for Pb(II)- and Bi(III)-Based Radiopharmaceuticals 0.43
Effect of Nb5+ Doping on Structural, Electronic, and Antibacterial Properties of Hydroxyapatite 0.22
1 0.21
GH001 vs Placebo in Patients With Treatment-Resistant Depression 0.21
1 0.25
Human antibody targeting Crimean-Congo hemorrhagic fever virus glycoprotein 38 protects mice against heterologous virus challenge 0.25
1 0.64
Prenatal Downregulation of CB1 Cannabinoid Receptors in the Mouse Prefrontal Cortex Disrupts Cortical Lamination and Induces a Transcriptional Signature Associated with Social Interaction Deficits 0.64
1 0.20
Sex‐specific metabolic responses to glucagon receptor agonism and modulation of the FGF21‐glucagon axis in female mice 0.20
5 1.58
Ladderanes: Stepping Up as Nonclassical ortho-Substituted Benzene Bioisosteres 0.25
Photoswitchable COX-2-Selective Inhibitors as Light-Regulated Anti-Inflammatory Agents 0.56
The Effect of Nonsolvent Post-Processing Induced Structural and Morphological Changes on the Optoelectronic Properties of CsPbBr3 Nanocrystals 0.13
Controlled Self-Immolative Release of β-Lapachone via an Optimized para-Hydroxybenzyl Linker for Targeted Pancreatic Cancer Therapy 0.25
Fast and Reliable NMR-Based Fragment Scoring for Drug Discovery 0.40
2 0.53
Extension Reports in Clinical Trials 0.44
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy 0.09
1 1.00
Deprescribing Through the LESS-CHRON Tool: Recruitment Data and Results of Impact on Pharmacological Treatment (LESS-CHRON Validation Project) 1.00
1 1.00
Hexadecylamine Addition Promotes Crystallization-Driven Functionalities in Freezing–Thaw PVA Hydrogels 1.00
2 0.18
Pharmacogenomics of antiepileptic drug mood stabilizer treatment response in bipolar disorder: A MoStGen Consortium study 0.11
A five-year risk prediction model of cardiovascular disease in individuals with bipolar disorder: a nationwide register study from Sweden 0.07
3 0.21
GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice 0.04
A µ-opioid receptor superagonist analgesic with minimal adverse effects 0.07
Inhibitors supercharge kinase turnover through native proteolytic circuits 0.10
1 0.04
Monovalent pseudo-natural products supercharge degradation of IDO1 by its native E3 KLHDC3 0.04
5 2.78
Structural dissection of the catalytic domain of the serine threonine kinase StkP of Streptococcus pneumoniae 0.10
Expanding the targeted protein degradation approach with small molecule chimeras directed to the 26S proteasome 1.00
The oncogenic CCDC6-RET fusion protein is a dual ATP- and ADP-dependent kinase 1.00
A resource to empirically establish drug exposure records directly from untargeted metabolomics data 0.05
An astrocytic ensemble at vHip-NAc synapses modulates cognitive impairments induced by chronic tetrahydrocannabinol exposure 0.63
3 0.12
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial 0.02
Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals 0.04
Lifetime Benefits of Comprehensive Medical Therapy in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 0.06
1 0.09
Distinct endocannabinoids specifically signal to astrocytes or neurons in the adult mouse hippocampus 0.09
1 0.10
Mechanical performance of hybrid polymer–lipid vesicles with leaflet asymmetry engineered using microfluidics 0.10
1 0.69
The allosteric landscape of the Src kinase 0.69
1 0.25
Adherence to legislation and recommendations to publicly post protocols and results of post-authorisation studies registered with European Medicines Agency: cross sectional study 0.25
2 0.12
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial 0.08
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials 0.05
2 0.31
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide 0.07
Ivermectin to Control Malaria — A Cluster-Randomized Trial 0.24

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.